Nutt D, Carhart-Harris R (2020) The current status of psychedelics in psychiatry. JAMA Psychiat. https://doi.org/10.1001/jamapsychiatry.2020.2171
Article
Google Scholar
Yaden DB, Griffiths RR (2020) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.0c00194
Article
Google Scholar
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2020) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. https://doi.org/10.1001/jamapsychiatry.2020.3285
Article
Google Scholar
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402–1411. https://doi.org/10.1056/NEJMoa2032994
CAS
Article
PubMed
Google Scholar
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619–627. https://doi.org/10.1016/s2215-0366(16)30065-7
Article
PubMed
Google Scholar
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399–408. https://doi.org/10.1007/s00213-017-4771-x
CAS
Article
PubMed
Google Scholar
Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 33(9):1088–1101. https://doi.org/10.1177/0269881119845793
Article
PubMed
Google Scholar
DiVito AJ, Leger RF (2020) Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. Mol Biol Rep 47(12):9791–9799. https://doi.org/10.1007/s11033-020-06009-x
CAS
Article
PubMed
Google Scholar
Krebs TS, Johansen PO (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 26(7):994–1002. https://doi.org/10.1177/0269881112439253
CAS
Article
PubMed
Google Scholar
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3):289–299. https://doi.org/10.1177/0269881114565144
CAS
Article
PubMed
Google Scholar
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735–1740
CAS
Article
Google Scholar
Spriggs MJ, Kettner H, Carhart-Harris RL (2020) Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. https://doi.org/10.1007/s40519-020-01000-8
Article
Google Scholar
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D’Souza DC (2020) Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. https://doi.org/10.1007/s13311-020-00962-y
Article
PubMed
Google Scholar
Inserra A, De Gregorio D, Gobbi G (2021) Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev 73(1):202–277. https://doi.org/10.1124/pharmrev.120.000056
Article
PubMed
Google Scholar
Teixeira PJ, Johnson M, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner HRCH (2021) Psychedelics and health behavior change. J Psychopharmacol (in press). https://doi.org/10.31234/osf.io/8vks6
Article
Google Scholar
Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264–355. https://doi.org/10.1124/pr.115.011478
CAS
Article
PubMed
PubMed Central
Google Scholar
Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35(25):2505–2511. https://doi.org/10.1016/0024-3205(84)90436-3
CAS
Article
PubMed
Google Scholar
González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior. Neuron 53(3):439–452. https://doi.org/10.1016/j.neuron.2007.01.008
CAS
Article
PubMed
Google Scholar
Weber ET, Andrade R (2010) Htr2a Gene and 5-HT(2A) Receptor expression in the cerebral cortex studied using genetically modified mice. Front Neurosci 4:36. https://doi.org/10.3389/fnins.2010.00036
CAS
Article
PubMed
PubMed Central
Google Scholar
Andrade R (2011) Serotonergic regulation of neuronal excitability in the prefrontal cortex. Neuropharmacology 61(3):382–386. https://doi.org/10.1016/j.neuropharm.2011.01.015
CAS
Article
PubMed
PubMed Central
Google Scholar
Burt JB, Preller KH, Demirtaş M, Ji JL, Krystal JH, Vollenweider FX, Anticevic A, Murray JD (2021) Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD. bioRxiv:2021.2001.2031.429016. https://doi.org/10.1101/2021.01.31.429016
Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL (2020) Structure of a hallucinogen-activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell 182(6):1574-1588.e1519. https://doi.org/10.1016/j.cell.2020.08.024
CAS
Article
PubMed
Google Scholar
Stenbæk DS, Madsen MK, Ozenne B, Kristiansen S, Burmester D, Erritzoe D, Knudsen GM, Fisher PM (2020) Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol 35(4):459–468. https://doi.org/10.1177/0269881120959609
CAS
Article
PubMed
Google Scholar
Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, Azinfar A, Oh WC, Wetsel WC, Olson DE, Tian L (2021) Psychedelic-inspired drug discovery using an engineered biosensor. Cell. https://doi.org/10.1016/j.cell.2021.03.043
Article
PubMed
PubMed Central
Google Scholar
Singleton SP, Luppi AI, Carhart-Harris RL, Cruzat J, Roseman L, Deco G, Kringelbach ML, Stamatakis EA, Kuceyeski A (2021) LSD flattens the brain’s energy landscape: evidence from receptor-informed network control theory. bioRxiv:2021.2005.2014.444193. https://doi.org/10.1101/2021.05.14.444193
Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci 118(17):e2022489118. https://doi.org/10.1073/pnas.2022489118
CAS
Article
PubMed
Google Scholar
Morales-Garcia JA, de la Fuente RM, Alonso-Gil S, Rodriguez-Franco MI, Feilding A, Perez-Castillo A, Riba J (2017) The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep 7(1):5309. https://doi.org/10.1038/s41598-017-05407-9
CAS
Article
PubMed
PubMed Central
Google Scholar
Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481–491. https://doi.org/10.1007/s00221-013-3579-0
CAS
Article
PubMed
Google Scholar
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23(11):3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
CAS
Article
PubMed
PubMed Central
Google Scholar
Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE (2020) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. https://doi.org/10.1038/s41586-020-3008-z
Article
PubMed
PubMed Central
Google Scholar
Ly C, Greb AC, Vargas MV, Duim WC, Grodzki ACG, Lein PJ, Olson DE (2020) Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.0c00065
Article
Google Scholar
Mason NL, Kuypers KPC, Müller F, Reckweg J, Tse DHY, Toennes SW, Hutten N, Jansen JFA, Stiers P, Feilding A, Ramaekers JG (2020) Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. https://doi.org/10.1038/s41386-020-0718-8
Article
PubMed
PubMed Central
Google Scholar
Vollenweider FX, Preller KH (2020) Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 21(11):611–624. https://doi.org/10.1038/s41583-020-0367-2
CAS
Article
PubMed
Google Scholar
Carhart-Harris RL (2019) How do psychedelics work? Curr Opin Psychiatry 32(1):16–21. https://doi.org/10.1097/yco.0000000000000467
Article
PubMed
Google Scholar
Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 7(1):13187. https://doi.org/10.1038/s41598-017-13282-7
CAS
Article
PubMed
PubMed Central
Google Scholar
Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL (2018) Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology 142:263–269. https://doi.org/10.1016/j.neuropharm.2017.12.041
CAS
Article
PubMed
Google Scholar
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2015) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 78(8):572–581. https://doi.org/10.1016/j.biopsych.2014.04.010
CAS
Article
PubMed
Google Scholar
Dos Santos RG, Bouso JC, Hallak JEC (2017) Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Ther Adv Psychopharmacol 7(4):141–157. https://doi.org/10.1177/2045125316689030
CAS
Article
PubMed
PubMed Central
Google Scholar
Leptourgos P, Fortier-Davy M, Carhart-Harris R, Corlett PR, Dupuis D, Halberstadt AL, Kometer M, Kozakova E, LarØi F, Noorani TN, Preller KH, Waters F, Zaytseva Y, Jardri R (2020) Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. Schizophr Bull. https://doi.org/10.1093/schbul/sbaa117
Article
PubMed
PubMed Central
Google Scholar
Carhart-Harris RL, Wagner AC, Agrawal M, Kettner H, Rosenbaum JF, Gazzaley A, Nutt DJ, Erritzoe D (2021) Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? J Psychopharmacol (Oxford, England):2698811211008567. https://doi.org/10.1177/02698811211008567
Kelly JR, Crockett MT, Alexander L, Haran M, Baker A, Burke L, Brennan C, O’Keane V (2021) Psychedelic science in post-COVID-19 psychiatry. Ir J Psychol Med 38(2):93–98. https://doi.org/10.1017/ipm.2020.94
CAS
Article
PubMed
Google Scholar
Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268–1278. https://doi.org/10.1177/0269881116662634
Article
PubMed
PubMed Central
Google Scholar
RANZCP (2020) The Royal Australian and New Zealand College of Psychiatrists (RANZCP). Therapeutic use of psychedelic substances. https://www.ranzcp.org/files/resources/college_statements/clinical_memoranda/cm-therapeutic-use-of-psychedelics.aspx
Kelly JR, Baker A, Babiker M, Burke L, Brennan C, O’Keane V (2019) The psychedelic renaissance: the next trip for psychiatry? Ir J Psychol Med 1–5. https://doi.org/10.1017/ipm.2019.39
Nutt D, Erritzoe D, Carhart-Harris R (2020) Psychedelic Psychiatry’s Brave New World. Cell 181(1):24–28. https://doi.org/10.1016/j.cell.2020.03.020
CAS
Article
PubMed
Google Scholar
Roche A, Kostadinov V, Chapman J, McEntee A (2020) Have decreases in young workers’ risky drinking resulted in an increase in illicit drug use? Health Promot J Austr. https://doi.org/10.1002/hpja.454
Article
PubMed
Google Scholar
Palamar JJ, Le A (2018) Trends in DMT and other tryptamine use among young adults in the United States. Am J Addict 27(7):578–585. https://doi.org/10.1111/ajad.12803
Article
PubMed
PubMed Central
Google Scholar
Yockey RA, Vidourek RA, King KA (2020) Trends in LSD use among US adults: 2015–2018. Drug Alcohol Depend 212:108071. https://doi.org/10.1016/j.drugalcdep.2020.108071
Article
PubMed
Google Scholar
Winstock AR, Timmermann C, Davis E, Maier LJ, Zhuparris A, Ferris JA, Barratt MJ, Kuypers KPC (2020) Global Drugs Survey (GDS) 2020 Psychedelics Key Findings Report
U.S. Department of Health and Human Services SAaMHSAS, Center for Behavioral Health Statistics and Quality (2019) (2019) Key Substance Use and Mental Health Indicators in the United States: results from the 2018 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf
Killion B, Hai AH, Alsolami A, Vaughn MG, Sehun OhP, Salas-Wright CP (2021) LSD use in the United States: trends, correlates, and a typology of us. Drug Alcohol Depend 223:108715. https://doi.org/10.1016/j.drugalcdep.2021.108715
Article
PubMed
Google Scholar
Addiction. EMCfDaD (2020) Impact of COVID-19 on patterns of drug use and drug-related harms in Europe, EMCDDA Trendspotter briefing
Wales DMFftCSfEa (2019) Drugs misuse: findings from the 2018/19 crime survey for England and Wales. https://www.gov.uk/government/statistics/drug-misuse-findings-from-the-2018-to-2019-csew
PHIRB (2011) National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch.Drug Use in Irelan
Grant JE, Lust K, Chamberlain SR (2019) Hallucinogen use is associated with mental health and addictive problems and impulsivity in university students. Addict Behav Rep 10. https://doi.org/10.1016/j.abrep.2019.100228
Wildberger JI, John CN, Hallock RM (2017) Perceptions of the medicinal value of hallucinogenic drugs among college students 1(2):50. https://doi.org/10.1556/2054.01.2017.008
Article
Google Scholar
Barnett BS, Siu WO, Pope HG Jr (2018) A survey of American psychiatrists’ attitudes toward classic hallucinogens. J Nerv Ment Dis 206(6):476–480. https://doi.org/10.1097/nmd.0000000000000828
Article
PubMed
Google Scholar
Winstock AR, Johnson MW (2019) Global drugs survey: the psychedelic revolution in psychiatry and why patient opinion matters so much. https://www.globaldrugsurvey.com/gds-2019/gds2019-the-psychedelic-revolution-in-psychiatry-and-why-patient-opinion-matters-so-much/
Statement on open science and open praxis with psilocybin, MDMA, and similar substances (2017) https://files.csp.org/open
Yaden DB, Yaden ME, Griffiths RR (2020) Psychedelics in psychiatry—keeping the renaissance from going off the rails. JAMA Psychiat. https://doi.org/10.1001/jamapsychiatry.2020.3672
Article
Google Scholar
Johnson MW (2020) Consciousness, religion, and gurus: pitfalls of psychedelic medicine. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.0c00198
Article
Google Scholar
Szmulewicz AG, Valerio MP, Smith JM (2015) Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. Int J Bipolar Disord 3:4–4. https://doi.org/10.1186/s40345-014-0020-y
Article
PubMed
PubMed Central
Google Scholar
Brown T, Shao W, Ayub S, Chong D, Cornelius C (2017) A Physician’s attempt to self-medicate bipolar depression with N, N-dimethyltryptamine (DMT). J Psychoactive Drugs 49(4):294–296. https://doi.org/10.1080/02791072.2017.1344898
Article
PubMed
Google Scholar
Abuse NIoD (2020) Substance Use in Women Research Report
Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams LA, Hui K, Hapke E (2020) Microdosing psychedelics: demographics, practices, and psychiatric comorbidities. J Psychopharmacol 34(6):612–622. https://doi.org/10.1177/0269881120908004
Article
PubMed
Google Scholar
Fadiman J, Korb S (2019) Might microdosing psychedelics be safe and beneficial? An initial exploration J Psychoactive Drugs 51(2):118–122. https://doi.org/10.1080/02791072.2019.1593561
Article
PubMed
Google Scholar
Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol 33(9):1039–1057. https://doi.org/10.1177/0269881119857204
CAS
Article
PubMed
PubMed Central
Google Scholar
Polito V, Stevenson RJ (2019) A systematic study of microdosing psychedelics. PLoS ONE 14(2):e0211023. https://doi.org/10.1371/journal.pone.0211023
CAS
Article
PubMed
PubMed Central
Google Scholar
Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS (2019) Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology 236(2):731–740. https://doi.org/10.1007/s00213-018-5106-2
CAS
Article
PubMed
Google Scholar
Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E (2019) Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J 16(1):43. https://doi.org/10.1186/s12954-019-0308-4
Article
PubMed
PubMed Central
Google Scholar
Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiat 86(10):792–800. https://doi.org/10.1016/j.biopsych.2019.05.019
CAS
Article
PubMed
Google Scholar
Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB (2019) The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology 236(4):1159–1170. https://doi.org/10.1007/s00213-018-5119-x
CAS
Article
PubMed
Google Scholar
Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2020) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237(3):841–853. https://doi.org/10.1007/s00213-019-05417-7
CAS
Article
PubMed
Google Scholar
Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D (2021) Self-blinding citizen science to explore psychedelic microdosing. eLife 10:e62878. https://doi.org/10.7554/eLife.62878
Olson DE (2020) The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.0c00192
Article
Google Scholar
Weston NM, Gibbs D, Bird CIV, Daniel A, Jelen LA, Knight G, Goldsmith D, Young AH, Rucker JJ (2020) Historic psychedelic drug trials and the treatment of anxiety disorders. Depress Anxiety. https://doi.org/10.1002/da.23065
Article
PubMed
Google Scholar
Medicine USNLo (2021) The safety and efficacy of psilocybin in participants with treatment resistant depression (P-TRD) (ClinicalTrials.gov). https://clinicaltrials.gov/ct2/show/NCT03775200?term=PSILOCYBIN
Medicine USNLo (2021) A Study of Psilocybin for Major Depressive Disorder (MDD). https://clinicaltrials.gov/ct2/show/NCT03866174?term=PSILOCYBIN
Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot’alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R, (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. https://doi.org/10.1038/s41591-021-01336-3
Article
PubMed
PubMed Central
Google Scholar
Castellanos JP, Woolley C, Bruno KA, Zeidan F, Halberstadt A, Furnish T (2020) Chronic pain and psychedelics: a review and proposed mechanism of action. Regional Anesthesia & Pain Medicine:rapm-2020–101273. https://doi.org/10.1136/rapm-2020-101273
Watts A (1968) Psychedelics and Religious Experience. Calif Law Rev 56(1):74–85. https://doi.org/10.2307/3479497
Article
Google Scholar
Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R (2019) Survey of subjective “God encounter experiences”: comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE 14(4):e0214377. https://doi.org/10.1371/journal.pone.0214377
CAS
Article
PubMed
PubMed Central
Google Scholar
Schultes RE, Hofmann A, Rätsch C (2001) Plants of the gods: their sacred, healing, and hallucinogenic powers. Healing Arts Press, Rochester, Vt
Google Scholar
Guzmán G (1983) The genus Psilocybe : a systematic revision of the known species including the history, distribution, and chemistry of the hallucinogenic species. J. Cramer, Vaduz [Liechtenstein]
Nutt D, King LA, Saulsbury W, Blakemore C (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369(9566):1047–1053. https://doi.org/10.1016/s0140-6736(07)60464-4
Article
PubMed
Google Scholar
Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, Egerton-Warburton D, Karro J, Kim C, Lenton S, Lubman DI, Pastor A, Rundle J, Ryan J, Gordon P, Sharry P, Nutt D, Castle D (2019) The Australian drug harms ranking study. J Psychopharmacol 33(7):759–768. https://doi.org/10.1177/0269881119841569
Article
PubMed
Google Scholar
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143–166. https://doi.org/10.1016/j.neuropharm.2018.05.012
CAS
Article
PubMed
PubMed Central
Google Scholar
Krebs TS, Johansen PØ (2013) Psychedelics and mental health: a population study. PLoS ONE 8(8):e63972. https://doi.org/10.1371/journal.pone.0063972
CAS
Article
PubMed
PubMed Central
Google Scholar
Rucker JJH, Iliff J, Nutt DJ (2018) Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology 142:200–218. https://doi.org/10.1016/j.neuropharm.2017.12.040
CAS
Article
PubMed
Google Scholar
Rucker JJ (2015) Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ 350:h2902. https://doi.org/10.1136/bmj.h2902
Article
PubMed
Google Scholar
Nutt DJ, King LA, Nichols DE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14(8):577–585. https://doi.org/10.1038/nrn3530
CAS
Article
PubMed
Google Scholar
Policy GCOD (2021) https://www.globalcommissionondrugs.org/reports
Werb D, Rowell G, Guyatt G, Kerr T, Montaner J, Wood E (2011) Effect of drug law enforcement on drug market violence: a systematic review. Int J Drug Policy 22(2):87–94. https://doi.org/10.1016/j.drugpo.2011.02.002
Article
PubMed
Google Scholar
Winstock A, Barratt M, Ferris JLM (2017) Global Drug Survey